[关键词]
[摘要]
目的 比较阿戈美拉汀与选择性五羟色胺再摄取抑制剂(SSRIs)治疗抑郁症的疗效和安全性。方法 计算机检索PubMed、EMBase、Cochrane图书馆、中国学术期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)和万方数据库,筛选阿戈美拉汀与SSRIs相比较治疗抑郁症的随机对照试验(RCT),比较阿戈美拉汀与SSRIs的疗效与不良反应(ADR)。检索时限从建库至2019年4月,采用RevMan 5.3统计软件进行Meta-分析。结果 共纳入12项RCTs,计3 292例患者。Meta-分析结果显示阿戈美拉汀与SSRIs治疗后总有效率、治愈率比较,差异无统计学意义;阿戈美拉汀较SSRIs恶心的发生率低,差异有统计学意义[RR=0.58,95% CI(0.47,0.72),P<0.000 01];致失眠发生率低,差异有统计学意义[RR=0.47,95% CI(0.32,0.69),P=0.000 1];致腹泻、便秘及多汗差异均有统计学意义,其他ADR发生率比较差异无统计学意义。结论 阿戈美拉汀治疗抑郁症与SSRIs疗效相当、安全性尚可,致ADR发生率不比SSRIs的高。
[Key word]
[Abstract]
Objective To systematically review the effect and safty for the treatment of depression comparing between agomelatin and selective serotonin reuptake inhibitors(SSRIs),and provide evidence-based reference for clinical treatment. Methods Retrieved from PubMed, EMBase, Cochrane Library, CBM, CNKI Database and VIP Database, randomized controlled trials (RCT) about the effect and safety for the treatment of depression comparing between agomelatin and SSRIs were collected,the retrieval period was up to April 2019 and Meta-analysis was performed by using Revman 5.3 software after data extracting. Results Totally 12 RCTs were enrolled, involving 3 292 patients. Results of Meta-analysis showed that there were no significant differences between agomelatin and SSRIs on response and remission rate. The incidence of nausea caused by agomelatin group were lower than SSRIs group[RR=0.58, 95% CI(0.47, 0.72), P<0.000 01],the incidence of insomnia caused by agomelatin group were lower than SSRIs group[RR=0.47, 95% CI(0.32, 0.69), P=0.000 1], there was significant difference in diarrhea, constipation. And hyperhidrosis between 2 groups. Conclusion The effect of agomelatine was similar to SSRIs and the safety was generally acceptable, there were no higher incidence of adverse reactions for the treatment of depression compared with SSRIs.
[中图分类号]
[基金项目]